Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Net Income (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Net Income for 14 consecutive years, with -$11.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income rose 46.44% year-over-year to -$11.9 million, compared with a TTM value of -$71.4 million through Dec 2025, up 31.8%, and an annual FY2025 reading of -$81.8 million, up 29.41% over the prior year.
  • Net Income was -$11.9 million for Q4 2025 at Enanta Pharmaceuticals, up from -$18.6 million in the prior quarter.
  • Across five years, Net Income topped out at -$11.9 million in Q4 2025 and bottomed at -$81.9 million in Q3 2021.
  • Average Net Income over 5 years is -$29.5 million, with a median of -$27.5 million recorded in 2022.
  • The sharpest move saw Net Income plummeted 267.11% in 2021, then soared 67.81% in 2022.
  • Year by year, Net Income stood at -$30.1 million in 2021, then increased by 3.75% to -$29.0 million in 2022, then dropped by 15.25% to -$33.4 million in 2023, then skyrocketed by 33.28% to -$22.3 million in 2024, then skyrocketed by 46.44% to -$11.9 million in 2025.
  • Business Quant data shows Net Income for ENTA at -$11.9 million in Q4 2025, -$18.6 million in Q3 2025, and -$18.3 million in Q2 2025.